Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial
Open accessThe DOI matches its Crossref record; 67 of the 71 references it cites were found in a registry or an index.
Abstract
Introduction: Obesity and smoking are the two leading causes of preventable death in the USA. Unfortunately, most smokers gain weight after quitting. Postcessation weight gain (PCWG) is frequently cited as one of the primary barriers to a quit attempt and a common cause of relapse. Further, excessive PCWG may contribute to the onset or progression of metabolic conditions, such as hyperglycaemia and obesity. The efficacy of the current treatments for smoking cessation is modest, and these treatments have no clinically meaningful impact on mitigating PCWG. Here, we outline a novel approach using glucagon-like peptide 1 receptor agonists (GLP-1RA), which have demonstrated efficacy in reducing both food and nicotine intake. This report describes the design of a double-blind, placebo-controlled, randomised clinical trial that evaluates the effects of the GLP-1RA exenatide as an adjunct to nicotine patches on smoking abstinence and PCWG. Methods and analysis: The study will be conducted at two university-affiliated research sites in Houston, Texas, the UTHealth Center for Neurobehavioral Research on Addiction and Baylor College of Medicine Michael E. DeBakey VA Medical Centre. The sample will consist of 216 treatment-seeking smokers with pre-diabetes (haemoglobin A1c of 5.7%–6.4%) and/or overweight (body mass index of 25 kg/m 2 or above). Participants will be randomised (1:1) to receive subcutaneous injections of placebo or 2 mg exenatide, once weekly for 14 weeks. All participants will receive transdermal nicotine replacement therapy and brief smoking cessation counselling for 14 weeks. The primary outcomes are 4-week continuous abstinence and changes in body weight at the end of treatment. The secondary outcomes are (1) abstinence and changes in body weight at 12 weeks post end of treatment and (2) changes in neuroaffective responses to cigarette-related and food-related cues as measured by electroencephalogram. Ethics and dissemination: The study has been approved by the UTHealth Committee for the Protection of Human Subjects (HSC-MS-21-0639) and Baylor College of Medicine Institutional Review Board (H-50543). All participants will sign informed consent. The study results will be disseminated via peer-reviewed publications and conference presentations. Trial registration number: NCT05610800.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Varying results have been reported for the role of GLP-1 and GLP-1 receptor agonists in inducing or maintaining abstinence from nicotine use (appendix pp 16-17), but the GLP-1 receptor agonist exenatide (given once weekly) increased abstinence by 70%.109”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the GLP-1 receptor agonist exenatide (given once weekly) increased abstinence by 70%.109”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [109]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of brief measures of positive and negative affect: The PANAS scales.
Watson, D., Clark, L. A., & Tellegen, A. (1988) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.54.6.1063 · Cited by 32,433
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
(1998) · PubMed · Cited by 10,216
brms : An R Package for Bayesian Multilevel Models Using Stan
Bürkner, P.-C. (2017) · Journal of Statistical Software · doi:10.18637/jss.v080.i01 · Cited by 9,476
The PHQ-8 as a measure of current depression in the general population
Kroenke, K., Strine, T. W., Spitzer, R. L., Williams, J. B. W., Berry, J. T., & Mokdad, A. H. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.06.026 · Cited by 5,121
Cuthbert, B. N., Schupp, H. T., Bradley, M. M., Birbaumer, N., & Lang, P. J. (2000) · Biological Psychology · doi:10.1016/s0301-0511(99)00044-7 · Cited by 1,900
Development of the World Health Organization Global Physical Activity Questionnaire (GPAQ)
Armstrong, T., & Bull, F. (2006) · Journal of Public Health · doi:10.1007/s10389-006-0024-x · Cited by 1,727
Hewson, P. (2015) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2014.12096_1.x · Cited by 1,367
How to get statistically significant effects in any ERP experiment (and why you shouldn't)
Luck, S. J., & Gaspelin, N. (2017) · Psychophysiology · doi:10.1111/psyp.12639 · Cited by 1,195 · cited 1×
“…(ie, pleasant, unpleasant, neutral, food and cigarette related) and, in line with previously published reports 57 58 and methodological recommendations, 59 the amplitude of the late positive potential (LPP) between 400 and 800 ms over a priori selected central and parietal sites will be computed.”
ResultCox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188
SOBELL, L. C., SOBELL, M. B., LEO, G. I., & CANCILLA, A. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb00485.x · Cited by 776
Berry, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1927 · Cited by 726
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Pan, A., Wang, Y., Talaei, M., Hu, F. B., & Wu, T. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00316-2 · Cited by 551
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543 · cited 1×
“19 20 Notably, GLP-1 receptor agonists (GLP-1RA) are currently used for the treatment of T2D and weight management in people with and without T2D.”
MethodAlhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 1×
“22 These brain regions are intimately associated with the regulation of food-related and nicotine-related reward.”
BackgroundWeight gain in smokers after quitting cigarettes: meta-analysis
Aubin, H.-J., Farley, A., Lycett, D., Lahmek, P., & Aveyard, P. (2012) · BMJ · doi:10.1136/bmj.e4439 · Cited by 510
Development and Validation of the Food‐Craving Inventory
White, M. A., Whisenhunt, B. L., Williamson, D. A., Greenway, F. L., & Netemeyer, R. G. (2002) · Obesity Research · doi:10.1038/oby.2002.17 · Cited by 471
Kirkpatrick, S. I., Subar, A. F., Douglass, D., Zimmerman, T. P., Thompson, F. E., Kahle, L. L., George, S. M., Dodd, K. W., & Potischman, N. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.083238 · Cited by 450
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427
Beyond good and evil: The time-course of neural activity elicited by specific picture content.
Weinberg, A., & Hajcak, G. (2010) · Emotion · doi:10.1037/a0020242 · Cited by 425
Smoking, Smoking Cessation, and Risk for Type 2 Diabetes Mellitus: A Cohort Study
Yeh, H.-C., Duncan, B. B., Schmidt, M. I., Wang, N.-Y., & Brancati, F. L. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-1-201001050-00005 · Cited by 360
Fryar, C. D., Carroll, M. D., & Ogden, C. L. (2018) · Cited by 357
Jin, S. ‐. C., Han, V. K. M., Simmons, J. G., Towle, A. C., Lauder, J. M., & Lund, P. K. (1988) · Journal of Comparative Neurology · doi:10.1002/cne.902710405 · Cited by 335 · cited 1×
“15–18 By stimulating insulin secretion and inhibiting glucagon secretion, GLP-1 regulates postprandial glucose excursions.”
BackgroundDevelopment and validation of the Wisconsin Smoking Withdrawal Scale.
Welsch, S. K., Smith, S. S., Wetter, D. W., Jorenby, D. E., Fiore, M. C., & Baker, T. B. (1999) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.7.4.354 · Cited by 306
Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality
Hu, Y., Zong, G., Liu, G., Wang, M., Rosner, B., Pan, A., Willett, W. C., Manson, J. E., Hu, F. B., & Sun, Q. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803626 · Cited by 259
Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire
Cappelleri, J. C., Bushmakin, A. G., Baker, C. L., Merikle, E., Olufade, A. O., & Gilbert, D. G. (2007) · Addictive Behaviors · doi:10.1016/j.addbeh.2006.06.028 · Cited by 241
The effect of tobacco cessation on weight gain, obesity, and diabetes risk
Bush, T., Lovejoy, J. C., Deprey, M., & Carpenter, K. M. (2016) · Obesity · doi:10.1002/oby.21582 · Cited by 223
GLP-1 acts on habenular avoidance circuits to control nicotine intake
Tuesta, L. M., Chen, Z., Duncan, A., Fowler, C. D., Ishikawa, M., Lee, B. R., Liu, X.-A., Lu, Q., Cameron, M., Hayes, M. R., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4540 · Cited by 200 · cited 1×
“Consistent with this, preclinical studies have shown that GLP-1RAs significantly decrease nicotine self-administration 23 and attenuate nicotine conditioned place preference.”
ResultMetabolic effects of smoking cessation
Harris, K. K., Zopey, M., & Friedman, T. C. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.32 · Cited by 196
Motivational interviewing with cocaine-dependent patients: A pilot study.
Stotts, A. L., Schmitz, J. M., Rhoades, H. M., & Grabowski, J. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.69.5.858 · Cited by 184
Self-citationBaker, T. B., Piper, M. E., Stein, J. H., Smith, S. S., Bolt, D. M., Fraser, D. L., & Fiore, M. C. (2016) · JAMA · doi:10.1001/jama.2015.19284 · Cited by 180
Cellular localization of proglucagon/glucagon‐like peptide I messenger RNAs in rat brain
Han, V. K. M., Hynes, M. A., Jin, C., Towle, A. C., Lauder, J. M., & Lund, P. K. (1986) · Journal of Neuroscience Research · doi:10.1002/jnr.490160110 · Cited by 178
Pomerleau, C. S., Zucker, A. N., & Stewart, A. J. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032105 · Cited by 175
The NIMH experimental medicine initiative
Insel, T. R. (2015) · World Psychiatry · doi:10.1002/wps.20227 · Cited by 165 · cited 1×
“26”
Borrelli, B., & Mermelstein, R. J. (1998) · Addictive Behaviors · doi:10.1016/s0306-4603(98)00014-8 · Cited by 164
Mills, E. J., Wu, P., Lockhart, I., Thorlund, K., Puhan, M., & Ebbert, J. O. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.705016 · Cited by 163 · cited 1×
“Informative priors will use extant information (eg, meta-analytical findings 61 for smoking outcomes).”
MethodEgecioglu, E., Engel, J. A., & Jerlhag, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077284 · Cited by 158 · cited 1×
“24 Further, our recent clinical trial of a GLP-RA extended-release exenatide showed that in the sample of 82 smokers who were prediabetic and/or overweight, 6 weeks treatment with exenatide resulted in a higher probability of abstinence and a lower probability of PCWG, compared with placebo.”
Cinciripini, P. M., Robinson, J. D., Karam-Hage, M., Minnix, J. A., Lam, C., Versace, F., Brown, V. L., Engelmann, J. M., & Wetter, D. W. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.678 · Cited by 136
Self-citationHeterogeneity in brain reactivity to pleasant and food cues: evidence of sign-tracking in humans
Versace, F., Kypriotakis, G., Basen‐Engquist, K., & Schembre, S. M. (2015) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsv143 · Cited by 127
Self-citationYammine, L., Green, C. E., Kosten, T. R., de Dios, C., Suchting, R., Lane, S. D., Verrico, C. D., & Schmitz, J. M. (2021) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntab066 · Cited by 124 · cited 2×
“…a strong premise for targeting GLP-1 receptors to facilitate smoking abstinence and mitigate PCW. Building on our previous 6-week trial of exenatide, 25 the current study will include a longer, 14-week, treatment duration and a post-treatment follow-up at 12 weeks after the end of treatment.”
BackgroundSelf-citationPredictors and Reasons for Relapse in Smoking Cessation with Nicotine and Placebo Patches
Nørregaard, J., Tønnesen, P., & Lj, P. (1993) · Preventive Medicine · doi:10.1006/pmed.1993.1021 · Cited by 122
Versace, F., Lam, C. Y., Engelmann, J. M., Robinson, J. D., Minnix, J. A., Brown, V. L., & Cinciripini, P. M. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00372.x · Cited by 105
Self-citationEffects of an intensive depression-focused intervention for smoking cessation in pregnancy.
Cinciripini, P. M., Blalock, J. A., Minnix, J. A., Robinson, J. D., Brown, V. L., Lam, C., Wetter, D. W., Schreindorfer, L., McCullough, J. P., Dolan-Mullen, P., et al. (2010) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0018168 · Cited by 88
Self-citationSmoking cessation and risk of type 2 diabetes mellitus: Korea Medical Insurance Corporation Study
Hur, N. W., Kim, H. C., Mo Nam, C., Ha Jee, S., Lee, H. C., & Suh, I. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000239474.41379.79 · Cited by 72
Versace, F., Frank, D. W., Stevens, E. M., Deweese, M. M., Guindani, M., & Schembre, S. M. (2018) · Psychophysiology · doi:10.1111/psyp.13309 · Cited by 70
Self-citationMolecular mechanisms underlying nutrient detection by incretin-secreting cells
Reimann, F. (2010) · International Dairy Journal · doi:10.1016/j.idairyj.2009.11.014 · Cited by 61 · cited 1×
“15–18 By stimulating insulin secretion and inhibiting glucagon secretion, GLP-1 regulates postprandial glucose excursions.”
BackgroundImpact of a motivational intervention on mechanisms of change in low-income pregnant smokers
Stotts, A. L., DeLaune, K. A., Schmitz, J. M., & Grabowski, J. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.02.063 · Cited by 61
Self-citationSiahpush, M., Singh, G. K., Tibbits, M., Pinard, C. A., Shaikh, R. A., & Yaroch, A. (2014) · Tobacco Control · doi:10.1136/tobaccocontrol-2012-050912 · Cited by 61
Kaufmann, A., Hitsman, B. L., Goelz, P. M., Veluz‐Wilkins, A. K., Blazekovic, S., Powers, L., Leone, F. T., Gariti, P., Tyndale, R. F., & Schnoll, R. A. (2015) · Addictive Behaviors · doi:10.1016/j.addbeh.2015.07.019 · Cited by 60
Effects of high dose transdermal nicotine replacement in cigarette smokers
Hatsukami, D. K., Mooney, M. E., Murphy, S. E., LeSage, M. G., Babb, D. A., & Hecht, S. S. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.12.017 · Cited by 50
Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation.
Cinciripini, P. M., Tsoh, J. Y., Wetter, D. W., Lam, C., de Moor, C., Cinciripini, L., Baile, W., Anderson, C., & Minna, J. D. (2005) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.13.4.282 · Cited by 44 · cited 1×
“The manual-driven counselling protocol has been used in previous studies, 33–35 and consists of once a week in-person sessions and 2 brief (10–15 min) supportive phone calls (at prequit and again at 3 days postquit), spanning the 14-week active treatment phase.”
MethodSelf-citationCalarco, C. A., & Picciotto, M. R. (2020) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntz010 · Cited by 40
Estimating statistical power for event‐related potential studies using the late positive potential
Gibney, K. D., Kypriotakis, G., Cinciripini, P. M., Robinson, J. D., Minnix, J. A., & Versace, F. (2019) · Psychophysiology · doi:10.1111/psyp.13482 · Cited by 39
Self-citationErratum: Metabolic effects of smoking cessation
Harris, K. K., Zopey, M., & Friedman, T. C. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.171 · Cited by 35
Predictors of Weight Change in Sedentary Smokers Receiving a Standard Smoking Cessation Intervention
Prod'hom, S., Locatelli, I., Giraudon, K., Marques-Vidal, P. M., Clair, C., Bize, R., & Cornuz, J. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts217 · Cited by 31
Krukowski, R. A., Bursac, Z., Little, M. A., & Klesges, R. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151290 · Cited by 30 · cited 1×
“7 62–65 Any characteristic that meets the criteria as a potential confounder will result in two models: one with covariate adjustment for that characteristic and a simple model without adjustment.”
BackgroundGray, K. M., McClure, E. A., Baker, N. L., Hartwell, K. J., Carpenter, M. J., & Saladin, M. E. (2015) · Addiction · doi:10.1111/add.12895 · Cited by 26
Pánková, A., Králíková, E., Štěpánková, L., Zvolská, K., Blaha, M., Štícha, M., Bortlíček, Z., Schroeder, D. R., & Croghan, I. T. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.10.010 · Cited by 24 · cited 1×
“7 62–65 Any characteristic that meets the criteria as a potential confounder will result in two models: one with covariate adjustment for that characteristic and a simple model without adjustment.”
BackgroundWebber, H. E., de Dios, C., Wardle, M. C., Suchting, R., Green, C. E., Schmitz, J. M., Lane, S. D., & Versace, F. (2021) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000450 · Cited by 20
Self-citationTaleb, Z. B., Ward, K. D., Asfar, T., Jaber, R., Bahelah, R. A., & Maziak, W. (2016) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntw223 · Cited by 18
Handschin, J., Hitsman, B. L., Blazekovic, S., Veluz‐Wilkins, A. K., Wileyto, E. P., Leone, F. T., Ashare, R. L., & Schnoll, R. A. (2017) · The Journal of Smoking Cessation · doi:10.1017/jsc.2017.2 · Cited by 18
Versace, F., Stevens, E. M., Robinson, J. D., Cui, Y., Deweese, M. M., Engelmann, J. M., Green, C. E., Karam‐Hage, M., Lam, C. Y., Minnix, J. A., et al. (2017) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntx264 · Cited by 17
Self-citationCollins, S. E., Eck, S., Kick, E., Schröter, M., Torchalla, I., & Batra, A. (2008) · Addictive Behaviors · doi:10.1016/j.addbeh.2008.12.008 · Cited by 15
Merchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5 · cited 1×
“In addition to the hypothalamus and brain stem, GLP-1 receptors are expressed throughout the mesolimbic dopamine system, 21 and GLP-1 containing neurons extend directly into the ventral tegmental area and nucleus accumbens.”
Background
Research works printed but not linked: 1
- 65. HPBD. Boca Raton. J R Stat Soc Ser A Stat Soc 2015;178:301.
Cited by
Wang, L., Berger, N. A., Kaelber, D. C., & Xu, R. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.04.029 · Cited by 130
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02498-5 · Cited by 83
“To gain access to the data, a request can be made to TriNetX (join@trinetx.com), but costs might be incurred, and a data-sharing agreement would be necessary.”
BackgroundMartinelli, S., Mazzotta, A. D., Longaroni, M., & Petrucciani, N. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.112424 · Cited by 70
Wang, L., Wang, Q., Li, L., Kaelber, D. C., & Xu, R. (2025) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djae260 · Cited by 53
Metadata
- Authors
- Yammine, L., Verrico, C. D., Versace, F., Webber, H. E., Suchting, R., Weaver, M. F., Kosten, T. R., Alibhai, H., Cinciripini, P. M., Lane, S. D., & Schmitz, J. M.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Michael E. DeBakey VA Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Houston (US)
- Corresponding author
- Yammine, Luba
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2023-06
- Volume
- 13
- Issue
- 6
- Pages
- e072707
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC10277057
- OpenAlex
- W4380685040
- Cited by
- 13
- References
- 71
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 6
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (acceptedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health, National Institute of Drug Abuse (1R01DA053241-01A1)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- exenatide, smoking cessation, nicotine patch, nicotine replacement therapy, GLP-1 receptor agonists, prediabetes, overweight, smoking abstinence, food cues, EEG, relapse
- MeSH terms
- Smokers, Exenatide, Humans, Nicotine, Obesity, Prediabetic State, Weight Gain, Randomized Controlled Trials as Topic, Smoking Cessation, Overweight, Tobacco Use Cessation Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.